These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 19031955

  • 1. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J, Kralovánszky J, Adleff V, Pap E, Németh K, Komlósi V, Kovács G.
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [Abstract] [Full Text] [Related]

  • 2. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
    Turello R, Rentsch K, Di Paolo E, Popovic MB.
    Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A, Zalacaín M, Marrodán L, San-Julián M, Sierrasesúmaga L.
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K, Book M, Zimmermann M, Meyer U, Welte K, Stanulla M, Reiter A.
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
    Lambrecht L, Sleurs C, Labarque V, Dhooge C, Laenen A, Sinnaeve F, Renard M, Uyttebroeck A.
    Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
    [Abstract] [Full Text] [Related]

  • 9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC.
    Cancer; 2004 Apr 15; 100(8):1724-33. PubMed ID: 15073863
    [Abstract] [Full Text] [Related]

  • 10. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
    Gammon DC, Bhatt MS, Patel B, Anderson M, Van Horn A, Glantz MJ.
    J Oncol Pharm Pract; 2008 Sep 15; 14(3):153-6. PubMed ID: 18719070
    [Abstract] [Full Text] [Related]

  • 11. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ, Lee J, Oguro T, Petrilli AS, Bordin JO.
    Am J Hematol; 2003 Mar 15; 72(3):209-11. PubMed ID: 12605394
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
    Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T.
    Cancer Res; 2005 Mar 15; 65(6):2482-7. PubMed ID: 15781665
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB, Mdhaffar M, Frikha R, Ghozzi H, Hakim A, Sahnoun Z, Elloumi M, Zeghal K.
    Adv Clin Exp Med; 2018 Aug 15; 27(8):1061-1068. PubMed ID: 29911750
    [Abstract] [Full Text] [Related]

  • 17. Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice.
    Celtikci B, Leclerc D, Lawrance AK, Deng L, Friedman HC, Krupenko NI, Krupenko SA, Melnyk S, James SJ, Peterson AC, Rozen R.
    Pharmacogenet Genomics; 2008 Jul 15; 18(7):577-89. PubMed ID: 18551038
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.
    Vagace JM, Caceres-Marzal C, Jimenez M, Casado MS, de Murillo SG, Gervasini G.
    Am J Hematol; 2011 Jan 15; 86(1):98-101. PubMed ID: 21064136
    [Abstract] [Full Text] [Related]

  • 19. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P, Giammarco S, Bellesi S, Metafuni E, Piccirillo N, De Ritis D, Marietti S, Federica S, Laurenti L, Fianchi L, Hohaus S, Giuseppe L, Sica S.
    Cancer Chemother Pharmacol; 2012 Mar 15; 69(3):691-6. PubMed ID: 21984221
    [Abstract] [Full Text] [Related]

  • 20. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
    Choi YJ, Park H, Lee JS, Lee JY, Kim S, Kim TW, Park JS, Kim JE, Yoon DH, Suh C.
    Hematol Oncol; 2017 Dec 15; 35(4):504-509. PubMed ID: 27781293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.